Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the World Health Organization (WHO) accidentally posted on its website.
In response to the leaked results, since taken down by the WHO, Gilead said that the trial was stopped early and so findings remain inconclusive.
In a statement, Gilead noted that the WHO posting included inappropriate characterisations of the study, stopped early due to low enrolment and cannot be used for ‘statistically meaningful conclusions’.
In addition, the company added: “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.
“We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future.”
